Study summary
Finerenone slowed kidney function loss in glomerular diseases including FSGS
42%reduction in albuminuria at 12 months
What was tested
Finerenone, a nonsteroidal mineralocorticoid receptor blocker pill, against placebo, in a prespecified analysis of people with glomerular diseases (215 with FSGS) within a larger kidney trial.
What they found
- Kidney function declined 3.50 vs 4.23 mL/min per year (difference 0.73).
- Albuminuria fell 42%, and the risk of kidney failure or major eGFR loss was 26% lower (hazard ratio 0.74).
What it means
Supports adding finerenone to kidney-protecting treatment, though it was an exploratory analysis.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.